+357 96 030922
info@marketpublishers.com

# U.S. Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), By Indication (Oncology, Infectious Diseases), And Segment Forecasts, 2025 - 2033

https://marketpublishers.com/r/U60D89A3854DEN.html
Date: September 2025
Pages: 150
Price: US$ 5,950.00 (Single User License)
ID: U60D89A3854DEN

## Abstracts

Market Size & Trends

The U.S. cell and gene therapy CDMO market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 10.34 billion by 2033, growing at a CAGR of 23.26% from 2025 to 2033. The market is driven by rising investments in advanced therapeutic modalities, increasing approvals of gene and CAR-T therapies, and the growing need for specialized manufacturing capacity. Pharmaceutical and biotech companies are increasingly partnering with CDMOs to overcome bottlenecks in viral vector production, cell expansion, and GMP-compliant facilities, as internal capabilities often cannot keep pace with the rapid innovation in this sector.

The market is primarily driven by the biotechnology and pharmaceutical industries' increased R&D funding and investments in cell and gene therapeutics (CGT). Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

+357 96 030922
info@marketpublishers.com

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production drive market growth. According to the data published by clinicaltrials.org, there are currently over 2,000 ongoing clinical trials in cell and gene therapies progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA's approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage.

Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

U.S. Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. cell and gene therapy CDMO market report based on phase, product, and indication.

Phase Outlook (Revenue, USD Million, 2021 - 2033)

Pre-clinical

Clinical

Product Outlook (Revenue, USD Million, 2021 - 2033)

Gene Therapy

Ex-vivo

In-vivo

+357 96 030922
info@marketpublishers.com

Gene-Modified Cell Therapy

CAR T-cell therapies

CAR-NK cell therapy

TCR-T cell therapy

Cell Therapy

Indication Outlook (Revenue, USD Million, 2021 - 2033)

Oncology

Infectious Diseases

Neurological disorders

Rare Diseases

Others

**This report can be delivered to the clients within 2 Business Days**

+357 96 030922
info@marketpublishers.com

# Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

# List Of Tables

## LIST OF TABLES

+357 96 030922
info@marketpublishers.com

# List Of Figures

## LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

## I would like to order

Product name: U.S. Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), By Indication (Oncology, Infectious Diseases), And Segment Forecasts, 2025 - 2033

Product link: https://marketpublishers.com/r/U60D89A3854DEN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U60D89A3854DEN.html